| CNM-Au8 / Clene |
| Completed | 2/3 | 161 | US | CNM-Au8, Matching Placebo | Merit E. Cudkowicz, MD, Clene Nanomedicine | Amyotrophic Lateral Sclerosis | 04/22 | 03/23 | | |
VISIONMS-LTE, NCT04626921: A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis |
|
|
| Completed | 2/3 | 55 | RoW | CNM-Au8 | Clene Nanomedicine, George Clinical | Relapsing Multiple Sclerosis | 05/23 | 09/23 | | |
| Active, not recruiting | 2/3 | 1500 | US | Zilucoplan, Verdiperstat, CNM-Au8, Pridopidine, SLS-005 Trehalose, ABBV-CLS-7262, DNL343 | Merit E. Cudkowicz, MD, Massachusetts General Hospital | Amyotrophic Lateral Sclerosis | 07/25 | 04/26 | | |
NCT05299658: An Open-Label Extension for the Phase 2 Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS |
|
|
| Active, not recruiting | 2 | 40 | RoW | CNMAu8 | Clene Nanomedicine | Amyotrophic Lateral Sclerosis | 11/24 | 12/24 | | |
REPAIR-MS, NCT03993171: 31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Multiple Sclerosis. |
|
|
| Recruiting | 2 | 30 | US | gold nanocrystals, CNM-Au8 | Clene Nanomedicine, University of Texas Southwestern Medical Center | Multiple Sclerosis | 12/24 | 12/24 | | |
NCT06408727: Intermediate Expanded Access Protocol CNMAu8.EAP04 |
|
|
| Available | N/A | | US | CNM-Au8 | Clene Nanomedicine, National Institute of Neurological Disorders and Stroke (NINDS) | ALS, Amyotrophic Lateral Sclerosis, PALS | | | | |
NCT04081714: Intermediate Expanded Access Protocol CNMAu8.EAP03 |
|
|
| Available | N/A | | US | CNM-Au8, Nanocrystalline gold | Clene Nanomedicine, University of Texas, Southwestern Medical Center at Dallas | Multiple Sclerosis | | | | |
| Available | N/A | | US | CNM-Au8, Nanocrystalline gold | Clene Nanomedicine | Amyotrophic Lateral Sclerosis | | | | |
| CNM-ZnAg / Clene |
NCT04610138: Study of ZnAg Liquid Solution to Treat COVID-19 Symptomatic Participants |
|
|
| Completed | 2 | 296 | RoW | CNM-ZnAg, Placebo | Clene Nanomedicine, ICL Pharma, Azidus Brazil | Covid19 | 05/22 | 10/22 | | |
